A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Latest Information Update: 11 Jun 2025
At a glance
- Drugs IRX 2 (Primary) ; Cyclophosphamide; Indometacin; Multivitamin; Omeprazole; Zinc
- Indications Head and neck cancer; Mouth neoplasm; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms INSPIRE
- Sponsors Ernexa Therapeutics; Eterna Therapeutics; IRX Therapeutics
Most Recent Events
- 25 Mar 2025 According to a Ernexa Therapeutics media release, the Eterna Therapeutics has changed its name to Ernexa Therapeutics.
- 07 May 2023 Status changed from active, no longer recruiting to completed.
- 26 Jul 2022 According to a Brooklyn ImmunoTherapeutics media release, the company expects to present he results of the INSPIRE study at a scientific conference later this year.